Calculer les besoins mondiaux en morphine pour la douleur dans les cas de cancer avancé et les quantités qui pourraient être fournies en fonction des estimations des besoins et de la consommation des pays

Publications

Calculer les besoins mondiaux en morphine pour la douleur dans les cas de cancer avancé et les quantités qui pourraient être fournies en fonction des estimations des besoins et de la consommation des pays

8 août 2022

Clark et al. analysent l'écart entre les besoins estimés en morphine, les besoins et la consommation actuels et concluent que moins d'un tiers des pays dans le monde répondent aux besoins des patients. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

By Joseph Clark, Lucia Crowther, Miriam J. Johnson , Christina Ramsenthaler, and David C. Currow / PLOS Global Public Health

Abstract
Lack of access to therapeutic opioids continuing causes global health inequalities. Access to morphine for symptom control is regulated under the terms of the Single Convention on Narcotics, countries must submit annual morphine requirement estimates and report consumption to the International Narcotics Control Board (INCB). INCB indicates access to morphine is increasing, however, estimated needs are unreported so changing proportions of needs feasibly met by requirements and consumption are unknown. Retrospective time series-analysis taking cross-sections every five years of gaps between calculated needs for morphine for people who die from cancer and total treatable using estimates of requirements and consumption (1997, 2002, 2007, 2012, 2017). We calculated need using INCB-recommended methods (80% of people who die from cancer require 67.5mg of morphine daily for 90 days (6.075g)) for countries reporting estimates and consumption using Global Burden of Disease cancer deaths by country. Gaps between calculated need and total treatable population using estimates and consumption were calculated. We report proportions of need feasibly met by estimates and consumption for included countries, by World Bank Income group. Global availability of morphine increased, from estimates sufficient to treat 86% of calculated needs in 1997, to 701% in 2017. However, proportion of countries estimating requirements feasibly meeting >100% of calculated needs rose only from 16% to 30%. Almost all Low-and-Middle-Income Countries submitted inadequate estimates with little change in 20 years. Consumption was lower than calculated needs at all time-points. Very few countries reported consumption greater than their estimate of requirement. Most countries submitted morphine estimates insufficient to meet analgesic needs of people who died from cancer. Estimates of requirements contextualise future Consumption, and increases in adequacy of estimates and consumption were minimal over 20 years. Annual publication of calculated morphine needs alongside estimates and consumption may be a key step to drive countries’ accountabilities.